tradingkey.logo
tradingkey.logo
検索

Cytek Biosciences Inc

CTKB
ウォッチリストに追加
4.220USD
-0.090-2.09%
終値 07-31 16:00ET15分遅れの株価
544.98M時価総額
損失額直近12ヶ月PER

詳細情報 Cytek Biosciences Inc 企業名

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Cytek Biosciences Incの企業情報

企業コードCTKB
会社名Cytek Biosciences Inc
上場日Jul 23, 2021
最高経営責任者「CEO」Jiang (Wenbin)
従業員数648
証券種類Ordinary Share
決算期末Jul 23
本社所在地47215 Lakeview Boulevard
都市FREMONT
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号94538
電話番号18779229835
ウェブサイトhttps://cytekbio.com
企業コードCTKB
上場日Jul 23, 2021
最高経営責任者「CEO」Jiang (Wenbin)

Cytek Biosciences Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.48M
+1.00%
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
4.80M
-2.83%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
150.01K
+10.38%
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
60.69K
+72.45%
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
59.68K
+73.68%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
59.68K
+73.68%
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.48M
+1.00%
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
4.80M
-2.83%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
150.01K
+10.38%
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
60.69K
+72.45%
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
59.68K
+73.68%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
59.68K
+73.68%

よくある質問

Cytek Biosciences Incの上位5名の株主は誰ですか?

Cytek Biosciences Incの上位5名の株主は以下のとおりです。Dr. Wenbin Jiang, Ph.D.

Cytek Biosciences Inc(CTKB)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Cytek Biosciences Incの株式を保有している機関は335社あり、保有株式の総市場価値は約84.13Mで、全体の65.16%を占めています。2025Q4と比較して、機関の持ち株は-7060937.00増加しています。

Cytek Biosciences Incの最大の収益源は何ですか?

2026Q1において、Biotechnology, pharmaceutical, distributor and CRO部門がCytek Biosciences Incにとって最大の収益を生み出しており、その金額は116.73Mで、全収益の57.93%を占めています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。